Application of terrain glucoside, an inhibitor of angiogenin secretion as a new drug for oral cancer therapy

• Project/Area Number: 26463041
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Surgical dentistry
• Research Institution: Okayama University
• Principal Investigator: Kishimoto Koji 岡山大学, 医歯薬学総合研究科, 助教 (40243480)
• Co-Investigator(Kenkyū-buntansha): 伊原木 聰一郎 岡山大学, 医歯薬学総合研究科, 助教 (80549866)
• Co-Investigator(Renkei-kenkyūsha): YOSHIOKA Norie 岡山大学, 大学院医歯薬学総合研究科, 助教 (50362984)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000); Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: terrein / angiogenin / 口腔癌 / 血管新生作用 / 腫瘍増殖抑制作用 / 新規口腔癌治療薬 / angiogenin分泌抑制作用 / VEGF分泌抑制作用 / 腫瘍血管新生作用 / 口腔癌分子標的治療薬 / angiognein(ANG) / 分子標的治療薬 / 米国

Outline of Final Research Achievements

This study assessed the effect of terrain, a bioactive fungal metabolite on oral cancer. Terrein inhibited angiogenin and VEGF secretions from oral cancer cells, both HSC-2 and SAS. Terrein also directly inhibited the proliferation both of the cancer cells. Furthermore, terrain inhibited a HSC-2 xenograft tumor growth in athymic mice through the inhibition of tumor cell proliferation and angiogenesis. These results suggest that terrein has a new lead compound for oral cancer therapy.

Research Products

• [Int'l Joint Research] タフツ大学分子腫瘍研究所(米国)
• [Journal Article] Synthetic Terrein Inhibits Progression of Head and Neck Cancer by Suppressing Angiogenin Production. (2016)
  • Author(s): Shibata A, Ibaragi S, Mandai H, Tsumur a T, Kishimoto K, Okui T, Hassan NM, Shimo T, Omori K, Hu GF, Takashiba S, Suga S, Sasaki A.
  • Journal Title: Anticancer Res. Volume: 36 Pages: 2161-2168
  • Peer Reviewed / Int'l Joint Research
• [Presentation] ANGIOGENIN IS A MOLECULAR TARGET FOR ORAL CANCER DRUG DEVELOPMENT (2014)
  • Author(s): K. Kishimoto, S. Yoshida, S. Ibaragi, N. Yoshioka, A. Shibata, A. Sasaki
  • Organizer: 22 Congress of the European Association for Cranio-Maxillo- Facial Surgery
  • Place of Presentation: Prague, Czech Republic
  • Year and Date: 2014-09-22 – 2014-09-26